Search

Qiwen Kuang,1,* Yuxiang Liang,2,* Yangjia Zhuo,2,* Zhiduan Cai,3 Funeng Jiang,2 Jianjiang Xie,2 Yu Zheng,4 Weide Zhong1,2,5,6 1Department of Urology, Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China; 2Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, People’s Republic of China; 3Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China; 4Department of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, People’s Republic of China; 5Department of Urology, Dejiang County People’s Hospital of Guizhou Province, Dejiang, Guizhou, People’s Republic of China; 6School of Medicine, Jinan University, Guangzhou, Guangdong, People’s Republic of China*These authors contributed equally to this workCorrespondence: Weide ZhongDepartment of Urology, Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, 1838, Guangzhoudadaobei, Baiyun District, Guangzhou, People’s Republic of ChinaTel +86 20 81048312Fax +86 20 83373322Email zhongwd2009@live.cnBackground: ALDOA plays an essential role in cancer progression in different human cancers; however, its function has not been understood in prostate cancer (PCa).Methods: Associations of ALDOA expression with clinicopathological features and patient prognosis in PCa were evaluated based on data obtained from the Taylor database and our clinical tissue microarray. The potential roles of ALDOA in malignant progression were verified using a series of in vivo and in vitro experiments after stable ALDOA overexpression and knockdown in DU145 and PC3 cell lines.